RESUMEN
BACKGROUND: Anaplastic thyroid carcinoma(ATC) is a rare pathological type of thyroid malignancy. Primary squamous cell carcinoma of thyroid(PSCCT) is now considered as a subtype of ATC, hereinafter referred to as ATC-SCC subtype. ATC-SCC subtype combined with follicular thyroid carcinoma is exceedingly rare, with fewer cases reported. The ATC-SCC subtype is a highly invasive tumor with a poor prognosis for patients after metastasis occurs, and current treatment of this type of tumor is tricky. CASE PRESENTATION: A 68-year-old female patient presented with a gradually growing swelling of right cervical region. Comprehensive auxiliary examinations and postoperative pathology confirmed the diagnosis of ATC-SCC subtype with follicular thyroid carcinoma, and the metastasis squamous cell carcinoma of the right cervical lymph nodes originates from ATC-SCC subtype. The patient received chemoradiotherapy postoperative. However, the residual cervical lymph nodes metastasis with squamous cell carcinoma still infiltrated surrounding structures in the neck extensively after palliative resection. The patient died 7 months after surgery. CONCLUSION: Our case highlights that cervical lymph node metastasis may be a significant factor in the poor prognosis of ATC-SCC subtype. This malignancy should be detected and treated early.
Asunto(s)
Adenocarcinoma Folicular , Metástasis Linfática , Carcinoma Anaplásico de Tiroides , Neoplasias de la Tiroides , Humanos , Femenino , Anciano , Neoplasias de la Tiroides/patología , Adenocarcinoma Folicular/patología , Adenocarcinoma Folicular/secundario , Carcinoma Anaplásico de Tiroides/patología , Carcinoma Anaplásico de Tiroides/diagnóstico , Carcinoma Anaplásico de Tiroides/terapia , Pronóstico , Resultado Fatal , Cuello/patología , Ganglios Linfáticos/patología , Carcinoma de Células Escamosas/secundario , Carcinoma de Células Escamosas/patología , Carcinoma de Células Escamosas/diagnósticoRESUMEN
RATIONALE: Follicular carcinoma of thyroid is a rare pathological type of thyroid carcinoma, accounting for 4.5% of the total. At present, the main treatment methods include surgery, iodine therapy, thyroid hormone inhibitors, etc. Targeted drug therapy is very important for distant metastasis and iodine-refractory differentiated thyroid cancer. PATIENT CONCERNS: This clinical case is a 51-year-old male patient with follicular carcinoma of thyroid. DIAGNOSES: After 7 years of total thyroidectomy, multiple distant metastasis occurred to bilateral lungs, bones, multiple lymph nodes, etc. INTERVENTION: After multidisciplinary consultation in the department of oncology, thoracic surgery, nuclear medicine and other departments, he received targeted drug therapy of Lenvatinib. OUTCOMES: After 3 months, his condition was partially relieved, and his quality of life was significantly improved. After 11 months of treatment, the evaluated efficacy was still in remission. LESSON: Late metastatic thyroid cancer is faced with dilemma of radioiodine refractory after traditional treatment. This will provide further evidence for therapeutic intervention in similar patients in the future.
Asunto(s)
Adenocarcinoma Folicular , Cuidados Paliativos , Neoplasias de la Tiroides , Tiroidectomía , Humanos , Masculino , Persona de Mediana Edad , Neoplasias de la Tiroides/patología , Neoplasias de la Tiroides/terapia , Adenocarcinoma Folicular/secundario , Adenocarcinoma Folicular/terapia , Adenocarcinoma Folicular/cirugía , Adenocarcinoma Folicular/patología , Tiroidectomía/métodos , Cuidados Paliativos/métodos , Compuestos de Fenilurea/uso terapéutico , Quinolinas/uso terapéutico , Antineoplásicos/uso terapéuticoRESUMEN
Background: For patients with thyroid cancer, distant metastasis is a significant predictor of poor outcome. Since distant metastasis occurs in less than 10% of patients with differentiated thyroid cancer, correlates of survival in this vulnerable patient population remain understudied. This study aimed to identify prognostic groups among patients with differentiated thyroid cancer and distant metastases and to determine the role of, and interactions between, patient and tumor characteristics in determining survival. Methods: We identified adult patients diagnosed with differentiated thyroid cancer with distant metastases from the U.S. SEER-17 cancer registry (2010-2019). Analyses were performed using Cox proportional hazards regression, survival trees, and random survival forest. Relative importance of patient and tumor factors important for disease-specific and overall survival was assessed based on the random survival forest analyses. Results: Cohort consisted of 2411 patients with differentiated thyroid cancer with distant metastases followed for a median of 62 months. Most common histopathologic subtype (86.0%) was papillary thyroid cancer, and the most common sites of distant metastasis were the lungs (33.7%) and bone (18.9%). Cox proportional hazards model illustrated significant associations between survival and the following: patient age (p < 0.001), tumor size (p < 0.01), and site of distant metastasis (p < 0.05). Survival tree analyses identified three distinct prognostic groups based on disease-specific survival (DSS) (5-year survival of the prognostic groups was 92%, 64%, and 41%; p < 0.001) and four distinct prognostic groups based on overall survival (OS) (5-year survival of the prognostic groups was 96%, 84%, 57%, and 31%; p < 0.001). The first split in the survival trees for DSS and OS was by age at diagnosis (≤57 years vs. ≥58 years) with subsequent splits based on presence/absence of lung metastases, tumor size (≤4 cm vs. >4 cm), and patient age. A total of 558 patients (23.1%) died from thyroid cancer, and 757 patients (31.4%) died from all causes during the study period. Conclusions: This study identifies distinct prognostic groups for patients with differentiated thyroid cancer with distant metastases and highlights the importance of patient age, lung metastases, and tumor size for determining both disease-specific and overall survival. These findings inform risk stratification and treatment decision-making in this understudied patient population.
Asunto(s)
Programa de VERF , Neoplasias de la Tiroides , Humanos , Neoplasias de la Tiroides/patología , Neoplasias de la Tiroides/mortalidad , Masculino , Femenino , Persona de Mediana Edad , Pronóstico , Adulto , Anciano , Estados Unidos/epidemiología , Neoplasias Pulmonares/mortalidad , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/secundario , Modelos de Riesgos Proporcionales , Metástasis de la Neoplasia , Neoplasias Óseas/secundario , Neoplasias Óseas/mortalidad , Cáncer Papilar Tiroideo/mortalidad , Cáncer Papilar Tiroideo/patología , Adenocarcinoma Folicular/mortalidad , Adenocarcinoma Folicular/patología , Adenocarcinoma Folicular/secundarioRESUMEN
The term noninvasive tumor with a follicular growth pattern and nuclear features of papillary thyroid cancer (NIFTP) is used to describe a tumor currently considered as a pre-malignant lesion for which a conservative therapeutic approach (i.e., lobectomy without radioiodine therapy) is strongly suggested. However, some patients with NIFTP and loco-regional or distant metastases have been already reported. We present an adult male patient with a final histological diagnosis of NIFTP and lymph node metastasis noted at post-therapy whole-body scintigraphy performed some days after radioiodine therapy.
Asunto(s)
Adenocarcinoma Folicular , Radioisótopos de Yodo , Metástasis Linfática , Neoplasias de la Tiroides , Humanos , Masculino , Neoplasias de la Tiroides/patología , Neoplasias de la Tiroides/diagnóstico por imagen , Neoplasias de la Tiroides/radioterapia , Metástasis Linfática/patología , Metástasis Linfática/diagnóstico por imagen , Adenocarcinoma Folicular/patología , Adenocarcinoma Folicular/secundario , Adenocarcinoma Folicular/diagnóstico por imagen , Adenocarcinoma Folicular/radioterapia , Radioisótopos de Yodo/uso terapéutico , Carcinoma Papilar/patología , Carcinoma Papilar/diagnóstico por imagen , Cáncer Papilar Tiroideo/patología , Adulto , Persona de Mediana Edad , Carcinoma/patología , Carcinoma/diagnóstico por imagen , Carcinoma/radioterapiaRESUMEN
A preoperative diagnosis of metastatic renal cell carcinoma to the thyroid (MRCCT) is important for determining clinical management but is challenging even in cases with a clinical history of renal cell carcinoma (RCC). This study aimed to elucidate the clinical, cytological, and pathological characteristics of MRCCT. Fourteen MRCCT cases extracted from 18 320 malignant thyroid tumors were included in this study. Twelve MRCCT (85.7%) occurred as solitary lesions and the most frequently suspected lesions on ultrasonography were follicular tumors. On cytology, 46.2% of cases were reported as RCC or suspected RCC; a medical history of RCC and immunocytochemistry were helpful in interpretation. RCC metastasized to a follicular adenoma in 50.0% of the solitary lesions. MRCCTs with a long interval from the initial presentation, solitary lesion, and Ki-67 labeling index <10% showed significantly longer disease-free survival. MRCCT is characterized by a long interval from the initial presentation of RCC, appearance as a solitary nodule, ultrasonographic similarity to follicular tumors, sharing cytological findings with primary thyroid tumors, and high frequency of metastasis within follicular adenoma. A long interval from the initial presentation, occurrence as a solitary lesion, and low Ki-67 labeling index may be favorable prognostic factors.
Asunto(s)
Adenocarcinoma Folicular , Carcinoma de Células Renales , Neoplasias Renales , Neoplasias de la Tiroides , Humanos , Adenocarcinoma Folicular/secundario , Carcinoma de Células Renales/patología , Pueblos del Este de Asia , Antígeno Ki-67 , Neoplasias Renales/patología , Neoplasias de la Tiroides/secundarioRESUMEN
BACKGROUND: Spinal metastases (SpMs) from thyroid cancers (TC) significantly reduce quality of life by causing pain, neurological deficits in addition to increasing mortality. Moreover, prognosis factors including surgery remain debated. METHODS: Data were stored in a prospective French national multicenter database of patients treated for SpM between January 2014 and 2017. Fifty-one consecutive patients affected by TC with 173 secondary SpM were included. RESULTS: Mean overall survival (OS) time for all patients from the diagnosis of a thyroid SpM event was 9.1 years (SD 8.7 months). The 1-year, 5-year and 10-year survival estimates were 94% (SD 3.3), 83.8.0% (SD 5.2), and 74.5% (SD 9.9). The median period of time between primary thyroid tumor diagnosis and the SpM event was 31.4 months (SD 71.6). In univariate analysis, good ECOG-PS (status 0 and 1) (p < 0.0001), ambulatory status (Frankel score) (p < 0.0001) and no epidural involvement (p = 0.01), were associated with longer survival, whereas cancer subtype (p = 0.436) and spine surgery showed no association (p = 0.937). Cox multivariate proportional hazard model only identified good ECOG-PS: 0 [HR: 0.3, 95% CI 0.1-0.941; p < 0.0001], 1 [HR: 0.8, 95% CI 0.04-2.124; p = 0.001] and ambulatory neurological status: Frankel E [HR: 0.262, 95% CI 0.048-1.443; p = 0.02] to be independent predictors of better survival. CONCLUSION: For cases presenting SpM from TC, we highlighted that the only prognostic factors were the progression of the cancer (ECOG-PS) and the clinical neurological impact of the SpM (Frankel status). Surgery should be discussed mainly for stabilization and neurological decompression.
Asunto(s)
Adenocarcinoma Folicular/secundario , Carcinoma Neuroendocrino/secundario , Neoplasias de la Columna Vertebral/secundario , Cáncer Papilar Tiroideo/secundario , Neoplasias de la Tiroides/patología , Adenocarcinoma Folicular/fisiopatología , Adenocarcinoma Folicular/terapia , Anciano , Carcinoma Neuroendocrino/fisiopatología , Carcinoma Neuroendocrino/terapia , Femenino , Humanos , Masculino , Metastasectomía , Persona de Mediana Edad , Rendimiento Físico Funcional , Modelos de Riesgos Proporcionales , Radioterapia , Neoplasias de la Columna Vertebral/fisiopatología , Neoplasias de la Columna Vertebral/terapia , Tasa de Supervivencia , Cáncer Papilar Tiroideo/fisiopatología , Cáncer Papilar Tiroideo/terapia , Neoplasias de la Tiroides/fisiopatología , Neoplasias de la Tiroides/secundario , Neoplasias de la Tiroides/terapia , Factores de TiempoRESUMEN
BACKGROUND: The term non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was recently proposed as a non-malignant thyroid lesion with indolent behavior that does not require post-operative radio-iodine treatment. We are reporting a case of NIFTP with bone metastasis that is the second case reported so far. CASE PRESENTATION: We describe a 38-year-old woman who presented with an indeterminate thyroid nodule and underwent total thyroidectomy with the finding of NIFTP on careful pathologic examination. However, her initial follow-up evaluation revealed a serum thyroglobulin level of > 300 ng/ml and a diagnostic whole body 131I scan demonstrated a focus of increased uptake in the left hemipelvis, confirmed on CT scan to be a lytic lesion in the left iliac bone. She was treated with 7.4GBq (200 mCi) of 131I and her follow-up 1 year later revealed an undetectable serum thyroglobulin and a negative whole body 131I scan with no visible uptake in the iliac bone indicating an excellent response. CONCLUSION: This case presentation reminds us to be alert to the rare occurrence of distant metastasis in NIFTP and the need for a case by case analysis and continuing post-operative follow-up for detection of residual or recurrent disease.
Asunto(s)
Adenocarcinoma Folicular/secundario , Neoplasias Óseas/secundario , Neoplasias de la Tiroides/patología , Nódulo Tiroideo/patología , Adenocarcinoma Folicular/diagnóstico por imagen , Adenocarcinoma Folicular/radioterapia , Adulto , Neoplasias Óseas/diagnóstico por imagen , Neoplasias Óseas/radioterapia , Núcleo Celular/patología , Femenino , Humanos , Ilion/diagnóstico por imagen , Radioisótopos de Yodo/uso terapéutico , Tomografía Computarizada por Tomografía Computarizada de Emisión de Fotón Único , Cáncer Papilar Tiroideo/patología , Neoplasias de la Tiroides/cirugía , Nódulo Tiroideo/cirugía , Tiroidectomía , Tomografía Computarizada por Rayos XRESUMEN
BACKGROUND: Thyroid crisis is a life-threatening condition in thyrotoxic patients. Although differentiated thyroid cancer is one of the causes of hyperthyroidism, reports on thyroid crisis caused by thyroid cancer are quite limited. Here, we describe a case of thyroid crisis caused by metastatic thyroid cancer. CASE PRESENTATION: A 91-year-old woman was admitted to our hospital because of loss of appetite. Two years prior to this hospitalization, she presented with subclinical thyrotoxicosis and was diagnosed with histologically unidentified thyroid cancer with multiple metastases, and she refused aggressive medical interventions. On admission, she exhibited extreme thyrotoxicosis, and the presence of fever, severe tachycardia, impaired consciousness, and heart failure revealed the presence of thyroid crisis. All thyroid autoantibodies were negative. Multidisciplinary conservative treatment was initiated; however, she died on the fifth day after admission. Autopsy revealed the presence of primary anaplastic thyroid carcinoma and multiple metastatic foci arising from follicular thyroid carcinoma. Both primary and metastatic follicular thyroid carcinoma likely induced thyrotoxicosis, which could have been exacerbated by anaplastic thyroid carcinoma. CONCLUSIONS: Even though the trigger of thyroid crisis in this patient is not clear, the aggravated progression of her clinical course suggests that careful monitoring of thyroid hormones and appropriate intervention are essential for patients with thyroid cancer.
Asunto(s)
Adenocarcinoma Folicular/complicaciones , Carcinoma Anaplásico de Tiroides/complicaciones , Crisis Tiroidea/etiología , Glándula Tiroides/patología , Neoplasias de la Tiroides/complicaciones , Adenocarcinoma Folicular/diagnóstico por imagen , Adenocarcinoma Folicular/patología , Adenocarcinoma Folicular/secundario , Anciano de 80 o más Años , Resultado Fatal , Femenino , Humanos , Pulmón/diagnóstico por imagen , Pulmón/patología , Neoplasias Pulmonares/diagnóstico por imagen , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/secundario , Carcinoma Anaplásico de Tiroides/diagnóstico por imagen , Carcinoma Anaplásico de Tiroides/patología , Crisis Tiroidea/diagnóstico por imagen , Glándula Tiroides/diagnóstico por imagen , Neoplasias de la Tiroides/diagnóstico por imagen , Neoplasias de la Tiroides/patología , Tomografía Computarizada por Rayos X , UltrasonografíaRESUMEN
Background: Brain metastases (BM) from differentiated thyroid cancer are rare. Stereotactic radiosurgery (SRS) is commonly used for the treatment of BMs; however, the experience with SRS for thyroid cancer BMs remains limited. The goal of this international, multi-centered study was to evaluate the efficacy and safety of SRS for thyroid cancer BMs. Methods: From 10 institutions participating in the International Radiosurgery Research Foundation, we pooled patients with established papillary or follicular thyroid cancer diagnosis who underwent SRS for histologically confirmed or radiologically suspected BMs. We investigated patient overall survival (OS), local tumor control, and adverse radiation events (AREs). Results: We studied 42 (52% men) patients who underwent SRS for 122 papillary (83%) or follicular (17%) thyroid cancer BMs. The mean age at SRS was 59.86 ± 12.69 years. The mean latency from thyroid cancer diagnosis to SRS for BMs was 89.05 ± 105.49 months. The median number of BMs per patient was 2 (range: 1-10 BMs). The median SRS treatment volume was 0.79 cm3 (range: 0.003-38.18 cm3), and the median SRS prescription dose was 20 Gy (range: 8-24 Gy). The median survival after SRS for BMs was 14 months (range: 3-58 months). The OS was significantly shorter in patients harboring ≥2 BMs, when compared with patients with one BM (Log-rank = 5.452, p = 0.02). Two or more BMs (odds ratio [OR] = 3.688; confidence interval [CI]: 1.143-11.904; p = 0.03) and lower Karnofsky performance score at the time of SRS (OR = 0.807; CI: 0.689-0.945; p = 0.008) were associated with shorter OS. During post-SRS imaging follow-up of 25.21 ± 30.49 months, local failure (progression and/or radiation necrosis) of BMs treated with SRS was documented in five (4%) BMs at 7.2 ± 7.3 months after the SRS. At the last imaging follow-up, the majority of patients with available imaging data had stable intracranial disease (33%) or achieved complete (26%) or partial (24%) response. There were no clinical AREs. Post-SRS peritumoral T2/fluid attenuated inversion recovery signal hyperintensity was noted in 7% BMs. Conclusion: The SRS allows durable local control of papillary and follicular thyroid cancer BMs in the vast majority of patients. Higher number of BMs and worse functional status at the time of SRS are associated with shorter OS in patients with thyroid cancer BMs. The SRS is safe and is associated with a low risk of AREs.
Asunto(s)
Neoplasias Encefálicas/secundario , Neoplasias Encefálicas/cirugía , Radiocirugia/métodos , Neoplasias de la Tiroides/patología , Adenocarcinoma Folicular/secundario , Adenocarcinoma Folicular/cirugía , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma Papilar/secundario , Carcinoma Papilar/cirugía , Femenino , Estudios de Seguimiento , Humanos , Estado de Ejecución de Karnofsky , Masculino , Persona de Mediana Edad , Supervivencia sin Progresión , Radiocirugia/efectos adversos , Análisis de Supervivencia , Resultado del Tratamiento , Adulto JovenRESUMEN
CONTEXT: Pregnancy-related hormones may stimulate thyroid cancer growth, but whether pregnancy affects the prognoses of patients with lung metastases from differentiated thyroid cancer (DTC-LM) after surgery and radioiodine therapy is unclear. OBJECTIVE: To assess the impact of pregnancy on DTC-LM through the comparison of prognoses between female patients with DTC-LM who did and did not become pregnant after surgery and radioiodine therapy. METHODS: We retrospectively analyzed the records of 124 female patients aged 16 to 35 years who underwent surgery and radioiodine therapy for DTC-LM. These patients were divided into pregnancy group (n = 37) and nonpregnancy group (n = 87) according to whether they became pregnant after surgery and radioiodine therapy, regardless of whether they had a pregnant history before treatment. RESULTS: The 5- and 10-year progression-free survival rates were 94.52% and 63.22% in pregnancy group versus 89.82% and 58.13% in nonpregnancy group. The 5- and 10-year cumulative overall survival rates of pregnancy group were 97.30% and 85.77% versus 93.50% and 81.95% in nonpregnancy group (all P > 0.05). The median time of follow-up in the pregnancy and nonpregnancy groups was 82 months (25-136 months) and 68 months (13-133 months), respectively. Non-radioiodine-avid LM and primary tumors needing repeated resection were independent predictors of poor progression-free survival for patients in pregnancy group. CONCLUSION: Pregnancy does not affect the prognoses of patients with DTC-LM after surgery and radioiodine therapy. Non-radioiodine-avid LM and repeated primary tumor surgeries are independent risk factors for poor prognoses of pregnant patients.
Asunto(s)
Adenocarcinoma Folicular/secundario , Neoplasias Pulmonares/secundario , Complicaciones Neoplásicas del Embarazo/patología , Cáncer Papilar Tiroideo/secundario , Neoplasias de la Tiroides/patología , Adenocarcinoma Folicular/mortalidad , Adenocarcinoma Folicular/radioterapia , Adolescente , Adulto , Femenino , Humanos , Radioisótopos de Yodo , Neoplasias Pulmonares/mortalidad , Neoplasias Pulmonares/radioterapia , Embarazo , Complicaciones Neoplásicas del Embarazo/mortalidad , Complicaciones Neoplásicas del Embarazo/radioterapia , Pronóstico , Estudios Retrospectivos , Tasa de Supervivencia , Cáncer Papilar Tiroideo/mortalidad , Cáncer Papilar Tiroideo/radioterapia , Neoplasias de la Tiroides/mortalidad , Neoplasias de la Tiroides/radioterapia , Resultado del Tratamiento , Adulto JovenRESUMEN
Patients with bone metastases are treated with long-term bone resorption inhibitors such as bisphosphonates and denosumab. However, resorption inhibitors have been known to cause fractures, such as atypical femoral fractures (AFFs). In recent years, there have been an increasing number of reports of atypical ulna fractures (AUFs) caused by bone resorption inhibitor usage. Treatment of AUFs is complicated, especially when they occur in patients with bone metastases, because it is difficult to discontinue bone resorption inhibitor treatment without the risk of aggravating metastatic lesions. Prophylactic surgery is recommended in AFFs when fractures are predicted, but there are few reports of prophylactic surgery for AUFs. Here, we report a case of incomplete AUF in a 74-year-old woman which was surgically treated with prophylactic plate fixation. The patient had been using denosumab for 6 years to treat bone metastases due to thyroid cancer. After surgery, no fractures were observed for 2 years without discontinuing denosumab, and her forearm function was adequate. AUFs are rare and difficult to treat, so oncologists who treat bone metastases need to pay special attention to diagnose this incomplete AUF before the fracture worsens. We believe that detection of a possible fracture and prophylactic surgery can improve prognosis.
Asunto(s)
Adenocarcinoma Folicular/tratamiento farmacológico , Conservadores de la Densidad Ósea/efectos adversos , Neoplasias Óseas/tratamiento farmacológico , Placas Óseas , Denosumab/efectos adversos , Fijación de Fractura/métodos , Procedimientos Quirúrgicos Profilácticos/métodos , Neoplasias de la Tiroides/patología , Fracturas del Cúbito/prevención & control , Adenocarcinoma Folicular/secundario , Anciano , Neoplasias Óseas/secundario , Femenino , Humanos , Fracturas del Cúbito/inducido químicamente , Fracturas del Cúbito/diagnóstico por imagen , Fracturas del Cúbito/cirugíaRESUMEN
Thyroid-like follicular carcinoma of the kidney (TLFCK) is a rare subtype of renal cell carcinoma, which closely resembles follicular neoplasms of the thyroid and has a distinctive indolent clinical behavior. Until now, a single case of TLFCK with extensive sarcomatoid differentiation has been documented with aggressive clinical course. We present an unusual case of sarcomatoid TLFCK with a low-grade spindle cell component in a 34-year-old male patient, with an indolent course following radical nephrectomy and regional node dissection.
Asunto(s)
Carcinoma de Células Renales/diagnóstico , Neoplasias Renales/diagnóstico , Riñón/patología , Adenocarcinoma Folicular/diagnóstico , Adenocarcinoma Folicular/secundario , Adulto , Carcinoma de Células Renales/patología , Carcinoma de Células Renales/cirugía , Diagnóstico Diferencial , Humanos , Riñón/cirugía , Neoplasias Renales/patología , Neoplasias Renales/cirugía , Masculino , Nefrectomía , Tomografía Computarizada por Tomografía de Emisión de Positrones , Glándula Tiroides/diagnóstico por imagen , Neoplasias de la Tiroides/diagnóstico , Neoplasias de la Tiroides/patologíaRESUMEN
Background: Aim of this study was to investigate the relationship between thyroglobulin doubling time (TgDT) and basal risk factors and metabolic parameters derived from 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in differentiated thyroid cancer (DTC). Materials and Methods: An analysis of 95 DTC patients who had rising serum thyroglobulin (Tg) levels under levothyroxine (LT4) suppression after radioiodine therapy was made. TgDT was calculated for 28/95 patients. The relationship between TgDT and basal demographic and histopathologic risk factors, preablative Tg, and antithyroglobulin antibody (ATg) levels and metabolic parameters was analyzed. Results: In 28 patients (15M, 13F, mean age: 52.6 ± 17.6) that TgDT could be calculated, 18F-FDG PET/CT was positive in 12 patients. Median TgDT was lower in 18F-FDG PET/CT positive patients compared to the negative cases (p < 0.05). Patients with skeletal metastasis or local recurrence had a shorter DT compared to the patients with lung metastasis. TgDT was correlated with peak standardized uptake value (SUVpeak) (p < 0.05). Maximum standardized uptake value (SUVmax) was correlated with tumor size (p < 0.05) and mean standardized uptake value (SUVmean) with tumor size and vascular invasion (p < 0.05). Median SUVmax and SUVmean were higher in follicular cancer or poor histological variants of papillary DTC compared to papillary cancer classical variant patients Conclusion: TgDT may be predictive of a positive 18F-FDG PET/CT in DTC. Skeletal metastasis and local recurrence are related to shorter TgDT. Greater tumor size, vascular invasion, and follicular cancer or poor variants of papillary carcinoma are related with higher SUVmax and SUVmean. Larger scale studies are needed to confirm results and to calculate a possible cutoff of TgDT for a positive 18F-FDG PET/CT study.
Asunto(s)
Adenocarcinoma Folicular/sangre , Neoplasias Óseas/sangre , Neoplasias Pulmonares/sangre , Recurrencia Local de Neoplasia/sangre , Tiroglobulina/sangre , Cáncer Papilar Tiroideo/sangre , Neoplasias de la Tiroides/sangre , Adenocarcinoma Folicular/diagnóstico por imagen , Adenocarcinoma Folicular/secundario , Adulto , Anciano , Autoanticuerpos/sangre , Vasos Sanguíneos/patología , Femenino , Fluorodesoxiglucosa F18 , Humanos , Masculino , Persona de Mediana Edad , Invasividad Neoplásica , Tomografía Computarizada por Tomografía de Emisión de Positrones , Factores de Riesgo , Cáncer Papilar Tiroideo/diagnóstico por imagen , Cáncer Papilar Tiroideo/secundario , Neoplasias de la Tiroides/diagnóstico por imagen , Neoplasias de la Tiroides/patología , Factores de Tiempo , Carga TumoralRESUMEN
Initial treatment for differentiated thyroid carcinoma (DTC) often consists of surgery and the administration of radioiodine. In this context, post-treatment Whole-Body Scans (ptWBS) are currently recommended, but data on its diagnostic accuracy are rare. The aim of the study was to evaluate the performance of ptWBS for distant metastasis in DTC patients. We included DTC patients who received radioiodine and underwent ptWBS between 2009-2015. The medical data were independently reviewed by two specialists to evaluate the concordance of positive distant ptWBS uptake and distant metastasis documented by imaging exams (gold standard). We studied 268 DTC patients. The mean age was 46±16 years (82% women), and papillary thyroid carcinoma was diagnosed in 87% of the patients. The median tumor size was 2.7 cm, 40% had lymph node involvement, and 11% had distant metastasis. Twenty-eight patients (10%) had distant ptWBS uptake, and nine of them (32%) were false-positives. In addition, nine false-negative ptWBS uptakes were identified. The overall performance of ptWBS showed 68% sensitivity and 96% specificity with significantly different performance according to the American Thyroid Association (ATA) risk groups. While the ptWBS performance for ATA low-intermediate-risk showed 29% sensitivity, 97% specificity, and Kappa of 0.19, the ATA high-risk group ptWBS displayed high sensitivity (82%), specificity (100%), and good agreement (Kappa 0.74). ptWBS is useful for a subgroup of ATA high-risk DTC patients. The overall poor performance of ptWBS suggests that it should be reconsidered for routine use in ATA at low to intermediate risk: the exam has little value to this subgroup.
Asunto(s)
Adenocarcinoma Folicular/secundario , Cáncer Papilar Tiroideo/secundario , Neoplasias de la Tiroides/patología , Tiroidectomía/métodos , Imagen de Cuerpo Entero/métodos , Imagen de Cuerpo Entero/normas , Adenocarcinoma Folicular/cirugía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Cáncer Papilar Tiroideo/cirugía , Neoplasias de la Tiroides/cirugíaRESUMEN
GLOBOCAN estimates 36 types of cancers in 185 countries based on the incidence, mortality, and prevalence in the year 2019. Nowadays, chemotherapy is the most widely used cancer treatment among immune, radio, hormone, and gene therapies. Here, we describe a very simple yet cost-effective approach that synergistically combines drug reconstitution, supramolecular nano-assembly, and tumor-specific targeting to address the multiple challenges posed by the delivery of the chemotherapeutic Gemcitabine (GEM) drug. The GEM prodrugs were gifted to impulsively self-assemble into excellent steady nanoparticles size on covalent conjugation of linoleic acid hydrophobic through amide group with â¼100 nm. Newly synthesized GEM-NPs morphology was confirmed by various electron microscopic techniques. After successful synthesis, we have evaluated the anticancer property of GEM and GEM-NPs against B-CPAP (papillary thyroid carcinoma) and FTC-133 (human follicular thyroid carcinoma) cancer cell lines. Further studies such as AO-EB (acridine orange-ethidium bromide), nuclear staining and flow cytometry analyses on cell death mechanism signified that the cytotoxicity was associated with apoptosis in thyroid cancer cells. GEM-NPs show excellent biocompatibility compared to GEM. The present study explained that GEM-NPs as a safe and hopeful strategy for chemotherapeutics of thyroid cancer therapy and deserve for further clinical evaluations.
Asunto(s)
Adenocarcinoma Folicular/tratamiento farmacológico , Desoxicitidina/análogos & derivados , Ácido Linoleico , Nanoconjugados , Polímeros , Profármacos/administración & dosificación , Cáncer Papilar Tiroideo/tratamiento farmacológico , Neoplasias de la Tiroides/tratamiento farmacológico , Adenocarcinoma Folicular/secundario , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Desoxicitidina/administración & dosificación , Desoxicitidina/farmacología , Portadores de Fármacos , Humanos , Microscopía Electrónica , Nanopartículas/ultraestructura , Profármacos/farmacología , Cáncer Papilar Tiroideo/secundario , Neoplasias de la Tiroides/patología , GemcitabinaRESUMEN
PURPOSE: Integrin αvß3, a member of the arginine-glycine-aspartate (RGD)-binding subfamily, is associated with tumor angiogenesis and metastasis. The aim of study is to investigate the clinical role of [99mTc]Tc-Galacto-RGD2 SPECT/CT in high-risk differentiated thyroid carcinoma (DTC) after thyroidectomy and radioactive iodine (RAI) therapy. METHODS: Thirty-six patients with high-risk DTC (20 males, 16 females; mean age: 59.9 ± 16.6 y) who underwent thyroidectomy and RAI therapy were consecutively enrolled in this study. All patients underwent [99mTc]Tc-Galacto-RGD2 SPECT/CT and diagnostic 131I whole-body scan 6 months after the last RAI treatment. A region of interest (ROI) was drawn and the ratio of tumor/non-target (T/NT) was calculated. Per-patient and per-lesion analysis was performed to evaluate the diagnostic efficacy. The final diagnosis was confirmed by histopathology and follow-up. Integrin αvß3, CD31, and Ki-67 expression in the tumor were also analyzed for evaluation of angiogenesis and proliferation. RESULTS: Out of 36 patients, twenty-two had metastatic disease. By per-patient analysis, the area under the curve of [99mTc]Tc-Galacto-RGD2 SPECT/CT was marginally significantly higher than that of 131I whole-body scan and morphological imaging (P = 0.0034 and 0.0006). For per-lesion analysis, [99mTc]Tc-Galacto-RGD2 SPECT/CT identified 67 metastatic lymph nodes in 14 patients, 12 lung metastases in four patients, and 12 bone metastases in six patients; its sensitivity was significantly higher than that of 131I whole-body scan in detection of lymphatic (90.54% vs. 55.41%, P = 0.0124) and bone metastasis (92.31% vs. 30.77%, P = 0.046). The ratio of T/NT in metastatic lesions increased with the DTC upstaging. CONCLUSIONS: [99mTc]Tc-Galacto-RGD2 SPECT/CT has high sensitivity in the detection of metastasis in high-risk DTC and further contributes to evaluation of tumor angiogenesis and radioiodine refractory status.
Asunto(s)
Adenocarcinoma Folicular/secundario , Carcinoma Papilar/secundario , Radioisótopos de Yodo/metabolismo , Compuestos de Organotecnecio/metabolismo , Neoplasias de la Tiroides/patología , Tiroidectomía/métodos , Adenocarcinoma Folicular/diagnóstico por imagen , Adenocarcinoma Folicular/metabolismo , Adenocarcinoma Folicular/terapia , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma Papilar/diagnóstico por imagen , Carcinoma Papilar/metabolismo , Carcinoma Papilar/terapia , Terapia Combinada , Femenino , Estudios de Seguimiento , Galactosa/química , Humanos , Radioisótopos de Yodo/química , Masculino , Persona de Mediana Edad , Oligopéptidos/química , Compuestos de Organotecnecio/química , Pronóstico , Radiofármacos/metabolismo , Neoplasias de la Tiroides/diagnóstico por imagen , Neoplasias de la Tiroides/metabolismo , Neoplasias de la Tiroides/terapia , Tomografía Computarizada de Emisión de Fotón Único/métodos , Tomografía Computarizada por Rayos X/métodos , Imagen de Cuerpo Entero , Adulto JovenRESUMEN
We retrospectively evaluated the frequency of unexpected accumulation of radioactive iodine on the post-therapy whole-body scan (Rx-WBS) after radioactive iodine (RAI) ablation therapy in patients with differentiated thyroid cancer (DTC). We searched our institutional database for Rx-WBSs of DTC patients who underwent RAI ablation or adjuvant therapy between 2012 and 2019. Patients with distant metastasis diagnosed by CT or PET/CT before therapy, and those had previously received RAI therapy were excluded. In total, 293 patients (201 female and 92 male, median age 54 years) were selected. Two nuclear medicine physicians interpreted the Rx-WBS images by determining the visual intensity of radioiodine uptake by the thyroid bed, cervical and mediastinal lymph nodes, lungs, and bone. Clinical features of the patients with and without the metastatic accumulation were compared by chi-square test and median test. Logistic regression analyses were performed to compare the association between the presence of metastatic accumulation and these clinical factors. Eighty-four of 293 patients (28.7%) showed metastatic accumulation. Patients with metastatic RAI accumulation showed a significantly higher frequency of pathological N1 (pN1) and serum thyroglobulin (Tg) > 1.5 ng/ml under TSH stimulation (p = 0.035 and p = 0.031, respectively). Logistic regression analysis indicated that a serum Tg > 1.5 ng/ml was significantly correlated with the presence of metastatic accumulation (odds ratio = 1.985; p = 0.033). In conclusion, Patients with Tg > 1.5 ng/ml were more likely to show metastatic accumulation. In addition, the presence of lymph node metastasis at the initial thyroid surgery was also associated with this unexpected metastatic accumulation.
Asunto(s)
Adenocarcinoma Folicular/diagnóstico por imagen , Neoplasias Óseas/diagnóstico por imagen , Radioisótopos de Yodo/uso terapéutico , Neoplasias Pulmonares/diagnóstico por imagen , Ganglios Linfáticos/diagnóstico por imagen , Cáncer Papilar Tiroideo/diagnóstico por imagen , Neoplasias de la Tiroides/diagnóstico por imagen , Adenocarcinoma Folicular/radioterapia , Adenocarcinoma Folicular/secundario , Adulto , Anciano , Neoplasias Óseas/secundario , Femenino , Humanos , Neoplasias Pulmonares/secundario , Masculino , Mediastino , Persona de Mediana Edad , Cuello , Estadificación de Neoplasias , Cintigrafía , Estudios Retrospectivos , Costillas/diagnóstico por imagen , Tomografía Computarizada por Tomografía Computarizada de Emisión de Fotón Único , Cáncer Papilar Tiroideo/radioterapia , Cáncer Papilar Tiroideo/secundario , Neoplasias de la Tiroides/patología , Neoplasias de la Tiroides/radioterapia , Tiroidectomía , Imagen de Cuerpo Entero , Adulto JovenRESUMEN
Thyroid-like follicular carcinoma of kidney (TLFCK) is a morphological subtype of renal cell carcinoma, which is included as an emerging/provisional entity in the classification of renal tumors, with only about 40 cases reported in literature. It has a distinct histological appearance and immunohistochemical profile as compared with other renal cell cancers. However, these tumors, while appearing distinctive, have not been characterized fully either morphologically or by ancillary techniques. The reported cases show variable demographical and clinical features. Most are indolent, while some present with metastasis. The histological, immunohistochemical, and ultrastructural features of a case of TLFCK with clusters of oncocytic cells and pseudosarcomatous stroma are presented. Follow-up of 5 years was uneventful. A review of literature to analyze features in metastatic as compared with non-metastatic TLFCK is discussed. We report a patient of TLFCK and compare the clinicopathological features of metastatic and non-metastatic tumors.
Asunto(s)
Adenocarcinoma Folicular/diagnóstico , Carcinoma de Células Renales/diagnóstico , Neoplasias Renales/diagnóstico , Riñón/patología , Células Oxífilas/patología , Adenocarcinoma Folicular/secundario , Adenocarcinoma Folicular/cirugía , Adulto , Biomarcadores de Tumor/análisis , Carcinoma de Células Renales/secundario , Carcinoma de Células Renales/cirugía , Diagnóstico Diferencial , Humanos , Riñón/citología , Riñón/cirugía , Neoplasias Renales/patología , Neoplasias Renales/cirugía , Masculino , NefrectomíaRESUMEN
This case report describes an elderly patient with radioiodine-resistant differentiated thyroid cancer and additional multiple metastases living in a rural setting, remote from the specialist oncology service. This case is of interest because effective systemic therapies for treatment-resistant cancers, such as lenvatinib, are now available but can potentially cause significant toxicities that require extensive medical management. Here, we discuss how patient care was provided collaboratively by the local community teams integrated with remote specialist oncology services. A 77-year-old patient presented with symptoms of cauda equina secondary to a large metastatic sacral deposit. The deposit was biopsied, and histology revealed a diagnosis of differentiated follicular thyroid cancer that was treated with external beam radiotherapy and thyroidectomy, followed by radioiodine. However, the disease was found to be resistant to radioiodine therapy, and the patient subsequently developed back pain due to new bone metastases. After further palliative external beam radiotherapy, the patient was started on systemic treatment with lenvatinib. Treatment has continued for more than 2.5 years with a slow but steady improvement in symptoms and quality of life. Monitoring and assessment of lenvatinib therapy and management of associated toxicities was coordinated remotely from a specialist cancer center over 200 miles away, using the skills of the local medical and nursing teams. This case report demonstrates how a cooperative effort using local teams and video-conferencing links to a specialist cancer center can be applied to safely treat a patient with a medication that may result in significant potential toxicities that require attentive and dynamic management.